Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Related Articles
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation
This randomized clinical trial evaluates the efficacy of sharing follow-up care between the specialty center and a local oncology practice after allogeneic hematopoietic cell transplantation.
Combination induces durable responses in advanced multiple myeloma
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination…
IMM-1-104 Regimens Yield Promising Activity in Pancreatic Cancer
Investigators of a phase 2a trial plan to include additional combination arms assessing treatment with IMM-1-104 across different patient populations.
Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India
This study assessed the diagnostic accuracy of mobile health (mHealth) screening for early detection of oral premalignant lesions and oral cancer in rural Varanasi, India.…
Rapid on‐site evaluation using telecytology: Quality assurance study at a high‐volume cancer center
Background Telecytology-assisted rapid on-site evaluation (ROSE) offers a cost-effective method to enhance minimally invasive biopsies like fine needle aspiration and core biopsies with touch prepar…
Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status
Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management
Highlighting American Cancer Society‐funded research in CA: A Cancer Journal for Clinicians
Click on the article title to read more.
FDA Grants Fast Track Designation to Invikafusp Alfa in TMB-H Colorectal Cancer
Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer.
